Modes of p53 Regulation

Cell

Volumn 137, Issue 4, 2009, Pages 609-622

  Kruse, Jan Philipp ^a   Gu, Wei ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ACETYLATION; DNA BINDING; DNA SEQUENCE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW;

MUS;

EID: 65549120715     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2009.04.050     Document Type: Review

References (150)

1. Abida W.M., Nikolaev A., Zhao W., Zhang W., and Gu W. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem. 282 (2007) 1797-1804
2. Allison S.J., Jiang M., and Milner J. Oncogenic viral protein HPV E7 upregulates the SIRT1 longivity protein in human cervical cancer cells. Aging 1 (2009) 316-327
3. An W., Kim J., and Roeder R.G. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117 (2004) 735-748
4. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
5. Ashcroft M., Kubbutat M.H., and Vousden K.H. Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19 (1999) 1751-1758
6. Ashcroft M., Taya Y., and Vousden K.H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20 (2000) 3224-3233
7. Ayed A., Mulder F.A., Yi G.S., Lu Y., Kay L.E., and Arrowsmith C.H. Latent and active p53 are identical in conformation. Nat. Struct. Biol. 8 (2001) 756-760
8. Baker S.J., Fearon E.R., Nigro J.M., Hamilton S.R., Preisinger A.C., Jessup J.M., vanTuinen P., Ledbetter D.H., Barker D.F., Nakamura Y., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244 (1989) 217-221
9. Barboza J.A., Iwakuma T., Terzian T., El-Naggar A.K., and Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol. Cancer Res. 6 (2008) 947-954
10. Bargonetti J., Friedman P.N., Kern S.E., Vogelstein B., and Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65 (1991) 1083-1091
11. Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., Hsieh J.K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33 (2003) 162-167
12. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004) 431-437
13. Blattner C., Tobiasch E., Litfen M., Rahmsdorf H.J., and Herrlich P. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18 (1999) 1723-1732
14. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003) 164-171
15. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21 (2006) 307-315
16. Brummelkamp T.R., Fabius A.W., Mullenders J., Madiredjo M., Velds A., Kerkhoven R.M., Bernards R., and Beijersbergen R.L. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2 (2006) 202-206
17. Cain C., Miller S., Ahn J., and Prives C. The N terminus of p53 regulates its dissociation from DNA. J. Biol. Chem. 275 (2000) 39944-39953
18. Carter S., Bischof O., Dejean A., and Vousden K.H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9 (2007) 428-435
19. Cawley S., Bekiranov S., Ng H.H., Kapranov P., Sekinger E.A., Kampa D., Piccolboni A., Sementchenko V., Cheng J., Williams A.J., et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116 (2004) 499-509
20. Chan W.M., Mak M.C., Fung T.K., Lau A., Siu W.Y., and Poon R.Y. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol. Cancer Res. 4 (2006) 15-25
21. Chao C., Hergenhahn M., Kaeser M.D., Wu Z., Saito S., Iggo R., Hollstein M., Appella E., and Xu Y. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J. Biol. Chem. 278 (2003) 41028-41033
22. Chao C., Herr D., Chun J., and Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 25 (2006) 2615-2622
23. Chao C., Wu Z., Mazur S.J., Borges H., Rossi M., Lin T., Wang J.Y., Anderson C.W., Appella E., and Xu Y. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26 (2006) 6859-6869
24. Chen D., Kon N., Li M., Zhang W., Qin J., and Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
25. Cheng H.L., Mostoslavsky R., Saito S., Manis J.P., Gu Y., Patel P., Bronson R., Appella E., Alt F.W., and Chua K.F. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA 100 (2003) 10794-10799
26. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
27. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
28. Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., McKinney K., Tempst P., Prives C., Gamblin S.J., et al. Regulation of p53 activity through lysine methylation. Nature 432 (2004) 353-360
29. Cummins J.M., Rago C., Kohli M., Kinzler K.W., Lengauer C., and Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428 (2004) 1 p following 486
30. Dai M.S., Zeng S.X., Jin Y., Sun X.X., David L., and Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 24 (2004) 7654-7668
31. Das S., Raj L., Zhao B., Bernstein A., Aaronson S.A., and Lee S.W. Hzf, a key modulator of p53 mediated transcription, functions as a critical determinant of cell survival and death upon genotoxic stress. Cell 130 (2007) 624-637
32. DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., and Old L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76 (1979) 2420-2424
33. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., and Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004) 86-92
34. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1 (1992) 45-49
35. Espinosa J.M., and Emerson B.M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8 (2001) 57-69
36. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., and Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275 (2000) 8945-8951
37. Feng L., Lin T., Uranishi H., Gu W., and Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25 (2005) 5389-5395
38. Finlay C.A., Hinds P.W., and Levine A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57 (1989) 1083-1093
39. Goodman R.H., and Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14 (2000) 1553-1577
40. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
41. Gu W., Malik S., Ito M., Yuan C.X., Fondell J.D., Zhang X., Martinez E., Qin J., and Roeder R.G. A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol. Cell 3 (1999) 97-108
42. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
43. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
44. Honda R., and Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18 (1999) 22-27
45. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 (1997) 25-27
46. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., and Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 444 (2006) 629-632
47. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., et al. p53 is regulated by the lysine demethylase LSD1. Nature 449 (2007) 105-108
48. Hupp T.R., Meek D.W., Midgley C.A., and Lane D.P. Regulation of the specific DNA binding function of p53. Cell 71 (1992) 875-886
49. Itahana K., Mao H., Jin A., Itahana Y., Clegg H.V., Lindstrom M.S., Bhat K.P., Godfrey V.L., Evan G.I., and Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12 (2007) 355-366
50. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., and Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20 (2001) 1331-1340
51. Iwabuchi K., Bartel P.L., Li B., Marraccino R., and Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA 91 (1994) 6098-6102
52. Iwakuma T., and Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 26 (2007) 2177-2184
53. Iyer N.G., Ozdag H., and Caldas C. p300/CBP and cancer. Oncogene 23 (2004) 4225-4231
54. Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., and La Thangue N.B. Arginine methylation regulates the p53 response. Nat. Cell Biol. 10 (2008) 1431-1439
55. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
56. Johnson T.M., Hammond E.M., Giaccia A., and Attardi L.D. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat. Genet. 37 (2005) 145-152
57. Jones S.N., Roe A.E., Donehower L.A., and Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 (1995) 206-208
58. Kaeser M.D., and Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99 (2002) 95-100
59. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., and Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science 252 (1991) 1708-1711
60. Kim E., Rohaly G., Heinrichs S., Gimnopoulos D., Meissner H., and Deppert W. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53. Oncogene 18 (1999) 7310-7318
61. Kim J.E., Chen J., and Lou Z. DBC1 is a negative regulator of SIRT1. Nature 451 (2008) 583-586
62. Knights C.D., Catania J., Di Giovanni S., Muratoglu S., Perez R., Swartzbeck A., Quong A.A., Zhang X., Beerman T., Pestell R.G., et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 173 (2006) 533-544
63. Krummel K.A., Lee C.J., Toledo F., and Wahl G.M. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 102 (2005) 10188-10193
64. Kruse J.P., and Gu W. MSL2 promotes MDM2 independent cytoplasmic localization of p53. J. Biol. Chem. 284 (2008) 3250-3263
65. Kruse J.P., and Gu W. SnapShot: p53 posttranslational modifications. Cell 133 (2008) 930
66. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
67. Kulikov R., Winter M., and Blattner C. Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J. Biol. Chem. 281 (2006) 28575-28583
68. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K.E., Baker L., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13 (2008) 454-463
69. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
70. Lane D.P., and Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278 (1979) 261-263
71. Laptenko O., and Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13 (2006) 951-961
72. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J.M., Lozano G., Hakem R., and Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112 (2003) 779-791
73. Leu J.I., Dumont P., Hafey M., Murphy M.E., and George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6 (2004) 443-450
74. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
75. Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., and Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416 (2002) 648-653
76. Li M., Luo J., Brooks C.L., and Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277 (2002) 50607-50611
77. Li M., Brooks C.L., Wu-Baer F., Chen D., Baer R., and Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302 (2003) 1972-1975
78. Li M., Brooks C.L., Kon N., and Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13 (2004) 879-886
79. Linares L.K., Hengstermann A., Ciechanover A., Muller S., and Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl. Acad. Sci. USA 100 (2003) 12009-12014
80. Linzer D.I., and Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17 (1979) 43-52
81. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., and Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19 (1999) 1202-1209
82. Liu Y., Lagowski J.P., Vanderbeek G.E., and Kulesz-Martin M.F. Facilitated search for specific genomic targets by p53 C-terminal basic DNA binding domain. Cancer Biol. Ther. 3 (2004) 1102-1108
83. Llanos S., Clark P.A., Rowe J., and Peters G. Stabilization of p53 by p14(ARF) without relocation of MDM2 to the nucleolus. Nat. Cell Biol. 3 (2001) 445-452
84. Lohrum M.A., Woods D.B., Ludwig R.L., Balint E., and Vousden K.H. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol. 21 (2001) 8521-8532
85. Lohrum M.A., Ludwig R.L., Kubbutat M.H., Hanlon M., and Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3 (2003) 577-587
86. Lowe S.W., and Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13 (2003) 77-83
87. Lu X., Ma O., Nguyen T.A., Jones S.N., Oren M., and Donehower L.A. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12 (2007) 342-354
88. Luo J., Su F., Chen D., Shiloh A., and Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408 (2000) 377-381
89. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107 (2001) 137-148
90. MacPherson D., Kim J., Kim T., Rhee B.K., Van Oostrom C.T., DiTullio R.A., Venere M., Halazonetis T.D., Bronson R., De Vries A., et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 23 (2004) 3689-3699
91. Marchenko N.D., and Moll U.M. The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle 6 (2007) 1718-1723
92. Marchenko N.D., Wolff S., Erster S., Becker K., and Moll U.M. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 26 (2007) 923-934
93. Marine J.C., and Jochemsen A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331 (2005) 750-760
94. Marine J.C., Francoz S., Maetens M., Wahl G., Toledo F., and Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 13 (2006) 927-934
95. Mayo L.D., and Donner D.B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 27 (2002) 462-467
96. Meek D.W. The p53 response to DNA damage. DNA Repair (Amst.) 3 (2004) 1049-1056
97. Melchior F., and Hengst L. SUMO-1 and p53. Cell Cycle 1 (2002) 245-249
98. Mellert H., Sykes S.M., Murphy M.E., and McMahon S.B. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle 6 (2007) 1304-1306
99. Meulmeester E., Pereg Y., Shiloh Y., and Jochemsen A.G. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 4 (2005) 1166-1170
100. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13 (2003) 49-58
101. Migliorini D., Denchi E.L., Danovi D., Jochemsen A., Capillo M., Gobbi A., Helin K., Pelicci P.G., and Marine J.C. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22 (2002) 5527-5538
102. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11 (2003) 577-590
103. Minsky N., and Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol. Cell 16 (2004) 631-639
104. Montes de Oca Luna R., Wagner D.S., and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
105. Ohkubo S., Tanaka T., Taya Y., Kitazato K., and Prives C. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J. Biol. Chem. 281 (2006) 16943-16950
106. Parant J., Chavez-Reyes A., Little N.A., Yan W., Reinke V., Jochemsen A.G., and Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29 (2001) 92-95
107. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000) 207-210
108. Poyurovsky M.V., Priest C., Kentsis A., Borden K.L., Pan Z.Q., Pavletich N., and Prives C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 26 (2007) 90-101
109. Ringshausen I., O'Shea C.C., Finch A.J., Swigart L.B., and Evan G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10 (2006) 501-514
110. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., and Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12 (1998) 2831-2841
111. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., Campargue I., Naumovski L., Crook T., and Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8 (2001) 781-794
112. Shangary S., Qin D., McEachern D., Liu M., Miller R.S., Qiu S., Nikolovska-Coleska Z., Ding K., Wang G., Chen J., et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 105 (2008) 3933-3938
113. Shangary S., and Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49 (2009) 223-241
114. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6 (2006) 663-673
115. Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., Dutta S., Appella E., and Gozani O. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27 (2007) 636-646
116. Shieh S.Y., Ikeda M., Taya Y., and Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 (1997) 325-334
117. Shieh S.Y., Ahn J., Tamai K., Taya Y., and Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14 (2000) 289-300
118. Sluss H.K., Armata H., Gallant J., and Jones S.N. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol. 24 (2004) 976-984
119. Song M.S., Song S.J., Kim S.Y., Oh H.J., and Lim D.S. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 27 (2008) 1863-1874
120. Stommel J.M., and Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23 (2004) 1547-1556
121. Sui G., Affar E.B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., and Grossman S.R. Yin Yang 1 is a negative regulator of p53. Cell 117 (2004) 859-872
122. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., and McMahon S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24 (2006) 841-851
123. Szak S.T., Mays D., and Pietenpol J.A. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21 (2001) 3375-3386
124. Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., El-Deiry W.S., and Yang X. Critical role for Daxx in regulating Mdm2. Nat. Cell Biol. 8 (2006) 855-862
125. Tang Y., Luo J., Zhang W., and Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24 (2006) 827-839
126. Tang Y., Zhao W., Chen Y., Zhao Y., and Gu W. Acetylation is indispensable for p53 activation. Cell 133 (2008) 612-626
127. Tanaka T., Ohkubo S., Tatsuno I., and Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 130 (2007) 638-650
128. Tasdemir E., Maiuri M.C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 10 (2008) 676-687
129. Thut C.J., Chen J.L., Klemm R., and Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267 (1995) 100-104
130. Tian C., Xing G., Xie P., Lu K., Nie J., Wang J., Li L., Gao M., Zhang L., and He F. KRAB-type zinc-finger protein Apak specifically regulates p53-dependent apoptosis. Nat. Cell Biol. (2009) 10.1038/ncb1864 in press Published online April 19, 2009
131. Toledo F., and Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6 (2006) 909-923
132. Tomita Y., Marchenko N., Erster S., Nemajerova A., Dehner A., Klein C., Pan H., Kessler H., Pancoska P., and Moll U.M. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 281 (2006) 8600-8606
133. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B.T., Qing W., Packman K., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103 (2006) 1888-1893
134. Trigiante G., and Lu X. ASPP [corrected] and cancer. Nat. Rev. Cancer 6 (2006) 217-226
135. Uldrijan S., Pannekoek W.J., and Vousden K.H. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 26 (2007) 102-112
136. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
137. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., and Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107 (2001) 149-159
138. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
139. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
140. Wahl G.M. Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death Differ. 13 (2006) 973-983
141. Wallace M., Worrall E., Pettersson S., Hupp T.R., and Ball K.L. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23 (2006) 251-263
142. Wang X., Taplick J., Geva N., and Oren M. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 56 (2004) 195-201
143. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., and Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1 (1999) 20-26
144. Wei C.L., Wu Q., Vega V.B., Chiu K.P., Ng P., Zhang T., Shahab A., Yong H.C., Fu Y., Weng Z., et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124 (2006) 207-219
145. Wu Z., Earle J., Saito S., Anderson C.W., Appella E., and Xu Y. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol. Cell. Biol. 22 (2002) 2441-2449
146. Xirodimas D.P., Saville M.K., Bourdon J.C., Hay R.T., and Lane D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118 (2004) 83-97
147. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (2005) 547-559
148. Yu G.W., Rudiger S., Veprintsev D., Freund S., Fernandez-Fernandez M.R., and Fersht A.R. The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. USA 103 (2006) 1227-1232
149. Zhang Y., Wolf G.W., Bhat K., Jin A., Allio T., Burkhart W.A., and Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 23 (2003) 8902-8912
150. Zhao W., Kruse J.P., Tang Y., Jung S.Y., Qin J., and Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451 (2008) 587-590